446. Comparative efficacy and acceptability of anxiolytic drugs for the treatment of anxiety disorders: a systematic review and network meta-analysis
T Mueller, A Kuenzi, B Kraemer, R von Kaenel, J Haettenschwiler, M Hilpert, C Imboden, E Holsboer-Trachsler, M Hatzinger, B Bandelow, E Seifritz, S Kasper · 2026
Read 446. Comparative efficacy and acceptability of anxiolytic drugs for the treatment of anxiety disorders: a systematic review and network meta-analysis by T Mueller, A Kuenzi, B Kraemer, R von Kaenel, J Haettenschwiler, M Hilpert, C Imboden, E Holsboer-Trachsler, M Hatzinger, B Bandelow, E Seifritz, S Kasper (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13556787.txt.
Description
T Mueller and co-authors compare anxiety drugs head to head in a systematic review and network meta-analysis. Presented in 2026 as a numbered conference abstract, the work pools trials for adults with anxiety disorders, above all generalized anxiety. Side effects and dependency risks make the choice of drug a careful one, the authors note.
The analysis covered 100 trials with 28,637 people, using records from 1980 to 2020. Most active drugs beat placebo at cutting anxiety. Clomipramine ranked highest for effect but also caused the most dropouts, while clobazam caused the fewest. Silexan, a lavender oil product and the only plant based drug in the set, scored high on effect and matched placebo on acceptability.
Catalog record
| CREATOR | T Mueller, A Kuenzi, B Kraemer, R von Kaenel, J Haettenschwiler, M Hilpert, C Imboden, E Holsboer-Trachsler, M Hatzinger, B Bandelow, E Seifritz, S Kasper |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |